OxSonics, a medtech firm developing ultrasound therapies launched out of Oxford University in July last year, has secured £2.7m ($4.49m) in a venture round led by venture firm Longwall Venture Partners. The UK-based company’s technology uses ultrasound devices combined with ultrasound-sensitive nanoparticles, which can provide real-time feedback to a clinician about whether drug delivery or…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
